Ciriaco Maraschiello joins Axxam as Chief Operating Officer
5 July 2023
News
Axxam announces the launch of Muna Therapeutics ApS with EUR 60 Million to advance novel small molecule therapeutics for neurodegenerative diseases
Axxam is proud to announce that Muna Therapeutics, a biotech company founded in 2020 by Aarhus University, financed by Novo Seeds and receiving assets in exchange of equity from Axxam, was successful closing a EUR 60 million (US$ 73 million) Series A financing round today.
Axxam is a member of the REsolution consortium
Axxam announces its participation in the REsolution consortium, a public-private research partnership supported by the Innovative Medicines Initiative (IMI), to accelerate research in the field of solute carrier (SLC) class of transporters.
Axxam acquires Hit Discovery Constance
Axxam is proud to announce the entire acquisition of the share capital of Hit Discovery Constance GmbH (“HDC”). As a consequence, HDC founded in 2014 as a joint venture between Axxam, Centre for Drug Design and Discovery of KU Leuven and Lead Discovery Center GmbH, is now a subsidiary of Axxam.
Symegold library for drug discovery services
Thanks to the long-standing collaboration with Symeres (recently rebranded from MercachemSyncom), Axxam has access to an additional library of approx. 80,000 lead-like compounds synthetized at Symeres, named Symegold library, for use in high-throughput screens.